Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Spanish Lung Cancer Group
Randomized, phase III, predictive pharmacogenomic, open, prospective, international, multicenter study in patients with non-small-cell lung carcinoma (NSCLC) after complete resection and with N1 or N2 involvement
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histological confirmation of non-small-cell lung carcinoma.
Complete surgical resection of the disease.
Tumoral tissue available for molecular analysis.
N1 (stage II) or N2 (stage IIIA) lymph node involvement in the study of the operative piece.
Men or women age 18 years or older.
Patients with a performance status of 2 or less according to the ECOG classification.
Patients with the following laboratory results: ANC \< 1500/L, Hb \< 10 g/dL, platelets \<100,000/L, bilirubin \< 1.0 mg/dL, AST and ALT \< 1.5 upper limit of normality, creatinine clearance \< 60 mL/min.
Complete recovery from surgery within 6 weeks.
Patients who have given written informed consent before initiating any specific study screening procedure.
You may not be if
Patients who have received previously chemotherapy or radiotherapy for the study disease.
Impossibility of complying with chemotherapy treatment due to cultural or geographic circumstances.
Patients with active infection, heart disease, or any other serious disease, in the judgment of the investigator.
Women who are pregnant or in the period of lactation.
Patients with a previous diagnosis of malignant disease in the last five years except for carcinoma in situ of the uterine cervix or skin cancer other than melanoma.
Patients under treatment with investigational agents.
